Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Percent of land use during the BASE20 and HG-2 (MRISSP5) scenario along with corresponding mean annual TN concentration values (mg/L) across all intake locations. by Elly T. Gay (21170097)

Geniposide(Gen) significantly decreased the levels of TNF-α and MIP-1α in BALF of bleomycin-induced PF mice. by Jian-Bin Yin (19556105)

Cardiac sympathetic fiber density decreased post-6-OHDA and correlated with <i>in vivo</i> and post mortem markers. by Jeanette M. Metzger (8259900)

Weighted odds ratios reflecting the impact of a genetically determined 10 mg/dL decrease in LDL-C on pre-specified atherosclerotic traits. by Aeron M. Small (9617751)

“…<p>Odds Ratio and 95% confidence interval is displayed for the effect of a genetically determined 10 mg/dL decrease in LDL-C on primary atherosclerotic traits for White individuals, Black individuals, Hispanic individuals, and inverse variance weighted meta-analysis of White, Black, and Hispanic populations (IVWMA). …”

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

RhpMS and DrmMS dose-response curves. by Megan Leander (459603)

“…<p>RhpMS dose dependently decreased <i>R</i>. <i>prolixus</i> cardiac contractility with an EC50 ∼ 140 nM. …”

PRV and HSV-1 employ US3 to decrease Bclaf1 in a proteasome-dependent manner. by Chao Qin (119135)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Top 10 pathways with the lowest p-value. by Rizka Fatriani (17485787)

“…Molecular docking results between PPARG and EP300 with the ten active compounds showed a binding affinity value of ≤ -5.0 kcal/mol in all dockings, indicating strong binding. …”

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

SRC-3 treatment decreased tumor growth in a Jeko-1 ibrutinib resistant mouse model. by Imani Bijou (18275174)

Effect of cilostazol on liver TNF-α (A), IL-6 (B), NFκβ (C) and TGFβ (D) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Large amounts of ingested phenylpyruvate are required to decrease the survival of adult <i>A. gambiae</i> mosquitoes. by Silke Fuchs (506300)

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. by Nicoletta Loberto (2224150)

The polarization of a passive straight cable due to an extracellular field is anti-symmetric and decreases with the field frequency. by Florian Aspart (3366014)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)